ArticleVeterinary and comparative oncology2013
Met interacts with EGFR and Ron in canine osteosarcoma.
Article in Veterinary and comparative oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Comparative aspects of targeted sentinel lymph node mapping in veterinary and human medicine: opportunities for future research.Frontiers in medicine · 2024Review
- Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery.Frontiers in veterinary science · 2022Review
- AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses.Cancer gene therapy · 2021Article
- Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?Theranostics · 2021Review
- Article
- Ursolic acid suppresses the biological function of osteosarcoma cells.Oncology letters · 2019Article
- The RTK Interactome: Overview and Perspective on RTK Heterointeractions.Chemical reviews · 2019Review
- miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.Cancer gene therapy · 2019Article
- Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.Frontiers in oncology · 2019Article
- Canine sarcomas as a surrogate for the human disease.Pharmacology & therapeutics · 2018Review
- Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.Acta veterinaria Scandinavica · 2017Review
- Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.BMC veterinary research · 2016Article
- Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs.Translational oncology · 2015Article
- Comparative oncology: what dogs and other species can teach us about humans with cancer.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- Epidermal growth factor signaling in transformed cells.International review of cell and molecular biology · 2015Review
- Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.ACS medicinal chemistry letters · 2014Article
- Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.Mechanisms of development · 2014Article
- Article
- Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts.BMC veterinary research · 2013Article
- Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The receptor tyrosine kinase (RTK) Met is known to be over-expressed in canine osteosarcoma (OSA). In human cancers, the RTKs Met, epidermal growth factor receptor (EGFR) and Ron are frequently co-expressed and engage in heterodimerization, altering signal transduction and promoting resistance to targeted therapeutics. We found that EGFR and Ron are expressed in canine OSA cell lines and primary tissues, EGFR and Ron are frequently phosphorylated in OSA tumour samples, and Met is co-associated with EGFR and Ron in canine OSA cell lines. Transforming growth factor alpha (TGFα) and hepatocyte growth factor (HGF) stimulation induced amplification of ERK1/2 and STAT3 phosphorylation in OSA cells and Met was phosphorylated following TGFα stimulation providing evidence for receptor cross-talk. Lastly, treatment of OSA cells with combined gefitinib and crizotinib inhibited cell proliferation in an additive manner. Together, these data support the notion that Met, EGFR and Ron interact in OSA cells and as such, may represent viable targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.